Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial

Luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, preserves renal function irrespective of acute changes in the estimated glomerular filtration rate in Japanese patients with type 2 diabetes

(2020) Kentaro Kohagura et al.   HYPERTENSION RESEARCH

Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial

(2020) Meg J. Jardine et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Fasting-Induced Natriuresis and SGLT: A New Hypothesis for an Old Enigma

(2020) Samuel N. Heyman et al.   Frontiers in Endocrinology

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

(2020) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice.

(2020) Megumi Oshima et al.   KIDNEY INTERNATIONAL

Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial

(2020) Bettina J. Kraus et al.   KIDNEY INTERNATIONAL

Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging

(2019) Kengo Kidokoro et al.   CIRCULATION

The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes

(2019) Daniël H. van Raalte et al.   DIABETES CARE

The new biology of diabetic kidney disease - mechanisms and therapeutic implications

(2019) Yuliya Lytvyn et al.   ENDOCRINE REVIEWS

The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial

(2019) Erik J.M. van Bommel et al.   KIDNEY INTERNATIONAL

Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes

(2018) Petter Bjornstad et al.   DIABETES CARE

Renoprotective effects of sodium-glucose cotransporter-2 inhibitors

(2018) Hiddo J.L. Heerspink et al.   KIDNEY INTERNATIONAL

Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and safety CardioVascular outcomes trial (VERTIS-CV)

(2018) Christopher P. Cannon et al.   AMERICAN HEART JOURNAL

Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial

(2018) Christoph Wanner et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Plasma uric acid effects on glomerular haemodynamic profile of patients with uncomplicated Type 1 diabetes mellitus

(2016) Y. Lytvyn et al.   DIABETIC MEDICINE

Uric Acid as a Biomarker and a Therapeutic Target in Diabetes

(2015) Yuliya Lytvyn et al.   Canadian Journal of Diabetes

Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

(2013) David Z.I. Cherney et al.   CIRCULATION

An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function

(2011) Frank A. Holtkamp et al.   KIDNEY INTERNATIONAL